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SUMMARY
Fluorescence-activatedcellsorting(FACS)strategiestopurifydistinctcelltypesfromthepooloffetalhumanmyoﬁber-associated(hMFA)
cells were developed. We demonstrate that cells expressing the satellite cell marker PAX7 are highly enriched within the subset of
CD45
 CD11b
 GlyA
 CD31
 CD34
 CD56
intITGA7
hi hMFA cells. These CD45
 CD11b
 GlyA
 CD31
 CD34
 CD56
intITGA7
hi cells lack
adipogenic capacity but exhibit robust, bipotent myogenic and osteogenic activity in vitro and engraft myoﬁbers when transplanted
into mouse muscle. In contrast, CD45
 CD11b
 GlyA
 CD31
 CD34
+ fetal hMFA cells represent stromal constituents of muscle that do
not express PAX7, lack myogenic function, and exhibit adipogenic and osteogenic capacity in vitro. Adult muscle likewise contains
PAX7
+ CD45
 CD11b
 GlyA
 CD31
 CD34
 CD56
intITGA7
hi hMFA cells with in vitro myogenic and osteogenic activity, although these
cells are present at lower frequency in comparison to their fetal counterparts. The ability to directly isolate functionally distinct progen-
itor cells from human muscle will enable novel insights into muscle lineage speciﬁcation and homeostasis.
INTRODUCTION
In mice, combinatorial surface marker analysis has been
useful in enabling direct discrimination and prospective
isolation of phenotypically and functionally distinct cells
from skeletal muscle using ﬂuorescence-activated cell sort-
ing (FACS) (Cerletti et al., 2008; Kuang et al., 2007; Sacco
et al., 2008; Sherwood et al., 2004; Tanaka et al., 2009).
FACShasbeenused topurifyPAX7-expressing mousesatel-
lite cells, which exhibit self-renewal and myogenic differ-
entiation capacities consistent with muscle stem cells
(Cerletti et al., 2008; Fukada et al., 2004; Kuang et al.,
2007; Montarras et al., 2005; Sacco et al., 2008; Sherwood
et al., 2004; Tanaka et al., 2009). Prospective isolation of
adult mouse satellite cells has also enabled studies that
distinguished their myogenic differentiation potential
from adipogenic/ﬁbrogenic activities in muscle (Joe et al.,
2010), revealed their contributions to muscle pathologies
(Cerletti et al., 2008; Chakkalakal et al., 2012; Conboy
et al., 2003; Sacco et al., 2008), and provided proof in
principle that they may be useful in cell therapy
approaches (Cerletti et al., 2008, 2012; Sacco et al., 2008).
A similar cell-sorting approach recently allowed puriﬁca-
tion of ﬁbroadipogenic precursors from mouse muscle
and showed that these cells lack myogenic capacity
(Joe et al., 2010; Uezumi et al., 2010). Together with
endothelial and inﬁltrating immune cells, these ﬁbroadi-
pogenic precursors constitute the muscle stroma and
play a critical role in regulating the early stages of muscle
repair after damage (Wang and Rudnicki, 2012). However,
in order to translate these ﬁndings to human muscle
and apply them for regenerative medicine, it is essential
to develop analogous strategies for prospective identiﬁca-
tion and isolation of human myogenic and adipogenic
precursors.
Lecourt et al. previously showedbyimmunoﬂuorescence
(IF) staining that cells in the satellite cell position in adult
human muscle lack CD34 (Lecourt et al., 2010). Pisani
et al. subsequently demonstrated that myogenic activity
couldbeenrichedinhumanadultmusclecellsbymagnetic
depletion of CD34
+ cells (Pisani et al., 2010b). However, as
described here, negative selection for CD34 achieves only
partial puriﬁcation of myogenic progenitors from human
fetal muscle. To establish more speciﬁc sorting strategies
capable of purifying human PAX7-positive cells, we under-
took a systematic study of surface markers that distinguish
phenotypically and functionally distinct cells in human
fetal muscle. These efforts identiﬁed a combination of
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population of PAX7-expressing CD45
 CD11b
 GlyA
 
CD31
 CD34
 CD56
intITGA7
hihumanmyoﬁber-associated
(hMFA) cells (hereafter referred to as CD34
 CD56
int
ITGA7
hi cells) from inﬁltrating blood cells and muscle-resi-
dent adipogenic precursors, allowing direct isolation of
each of these populations by FACS. Consistent with studies
in the mouse, human PAX7-expressing CD34
 CD56
int
ITGA7
hi cells are robustly myogenic and lack adipogenic
potential. PAX7-expressing CD34
 CD56
intITGA7
hi cells
with myogenic activity in vitro are also present in adult
muscle, but at lower frequency than in fetal tissue. Clonal
analysis in vitro further revealed a surprising bipotency of
humanfetalPAX7-expressingCD34
 CD56
intITGA7
hicells,
which exhibited both myogenic and osteogenic poten-
tial. In contrast, CD45
 CD11b
 GlyA
 CD31
 CD34
+ fetal
hMFA cells (abbreviated CD34
+ cells), which exhibited
potent adipogenic and osteogenic activity, lack PAX7
and show no myogenic potential. Taken together, these
studies report efﬁcient methods for the direct isolation
of highly enriched human fetal bipotent myogenic/
osteogenic and adipogenic progenitors. These protocols
provide tools for uncovering the cellular mechanisms and
environmental interactions that sustain human skeletal
muscle.
RESULTS
Human Fetal Skeletal Muscle Contains Multiple,
Distinct Cell Populations
To evaluate phenotypic and functional heterogeneity
among fetal hMFA cells, we adapted previously established
protocols for mouse myoﬁber-associated cell isolation
(Conboy et al., 2003; Sherwood et al., 2004) to liberate
the mononuclear cell fraction from human fetal muscle
(Ehrhardt et al., 2007; Tanaka et al., 1995). Plating hMFA
cells under myogenic, adipogenic, or osteogenic con-
ditions in vitro revealed signiﬁcant functional heterogene-
ity. Under myogenic conditions, hMFA cells formed
DESMIN-expressing multinucleated myotubes. Under adi-
pogenic conditions, hMFA cells differentiated into oil red
O (ORO)-positive, lipid droplet-containing adipocytes.
Under osteogenic conditions, hMFA cells produced
Alizarin-red (AR)-positive calcium deposits consistent
with osteogenic differentiation (Figure 1A).
We next evaluated phenotypic heterogeneity within the
hMFA pool using cell surface marker staining and FACS.
Existing literature was surveyed to identify candidate anti-
genic markers that might discriminate live myogenic from
nonmyogenic cells (Fukada et al., 2004; Kuang et al., 2007;
Lecourt et al., 2010; Pisani et al., 2010a, 2010b; Sacco et al.,
2008; Sherwood et al., 2004). PAX7, the canonical marker
of muscle satellite cells in mouse and human postnatal
muscle (Bosnakovski et al., 2008; Seale et al., 2000), is inap-
propriate for such an approach because as a nuclear
protein, antibody staining requires cell ﬁxation/permeabi-
lization. Flow cytometric analysis of hMFA cells revealed
differential expression of 11 candidate cell surface markers
(CD45, CD11b, glycophorin A [GlyA], b1 integrin, CD34,
CD56, ITGA7, CD90, CD13, and CXCR4; Figure 1B and
Figure S1A available online). A total of 9.1% ± 1.7%
(mean ± SD) of fetal hMFA cells expressed hematopoietic
lineage markers (CD45, CD11b, and GlyA) and CD31, an
endothelial marker (Figure 1B) (Andukuri et al., 2013).
Expression of CD34, CD56, and ITGA7 was detected in
55% ± 10.8%, 40.5% ± 7.0%, and 55.9% ± 9.2% of cells,
respectively (mean ± SD; Figures 1B and S1A–S1C). Other
markers analyzed included CD29, CD90, CD13, and
CXCR4, which were expressed by 90.4% ± 9.4% (CD29),
63.9% ± 10.3% (CD90), 38.4% ± 3.8% (CD13), and
63.2% ± 10.3% (CXCR4) of cells, respectively (mean ±
SD; Figures 1B and S1D–S1F). These analyses conﬁrmed
heterogeneity of cell surface marker expression by fetal
hMFAcells.Wethereforesoughttoexploitthisheterogene-
ity to fractionate fetal hMFA subsets with distinct differen-
tiation potentials.
CD45
 CD11b
 GlyA
 CD31
 CD34
 CD56
intITGA7
hi
Fetal hMFA Cells Are Enriched for PAX7-Expressing
Cells
Satellite cells are canonically recognized by expression of
the paired box transcription factor PAX7, which controls
transcription of myogenic genes such as MyoD and Myf5
(McKinnell et al., 2008) and is present in satellite cells as
well as muscle progenitors in postnatal muscle tissue. A
total of 27.5% ± 1% (mean ± SD) of fetal hMFA cells
expressed PAX7 by IF analysis (Figures 2B and S2). To assess
PAX7 expression by IF in fetal hMFA cell subsets, cells were
isolated by FACS after combinatorial staining for differen-
tially expressed cell surface markers (Figure 1C). Exclusion
of cells expressing CD45, CD11b, GlyA, and CD31 (which
mark hematopoietic and endothelial lineage cells) and
selection of CD34
 /low cells identiﬁed a population en-
riched for PAX7-expressing cells (55% ± 5% PAX7
+,
mean ± SD; Figure 2B). These CD45
 CD11b
 GlyA
 
CD31
 CD34
 /lowcells are hereafter designated ‘‘CD34
 /low
cells’’ (marked in pink in Figure 1C). None of the
CD45
 CD11b
 GlyA
 CD3
 CD34
+ cells (hereafter desig-
nated ‘‘CD34
+ cells’’ and marked in cyan in Figure 1C) ex-
pressed PAX7 (Figure 2). Thus, CD34
 /low hMFA cells
fromfetalmuscleareselectivelyenrichedforPAX7-express-
ing cells.
To further enrich PAX7
+ cells within the CD34
 /low
hMFA cell subset, we evaluated expression of additional
surface markers (Figure 1B). Differential expression of
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FACS Isolation of Progenitors from Human MuscleCD90, CD13, and CD29 did not discriminate candidate
populations within the CD34
 /low hMFA cell pool, as
CD90 and CD13 expression was enriched in the CD34
+
cell subset and CD29 was uniformly expressed by
CD34
 /low cells (data not shown). In contrast, differential
expressionofCD56 andITGA7distinguishedthreepopula-
tions within CD34
 /low fetal hMFA cells: CD34
 CD56
hi
ITGA7
low (marked in blue in Figure 1C), CD34
 CD56
int
ITGA7
hi (marked in red in Figure 1C), and CD34
 /low
CD56
 ITGA7
low (marked in green in Figure 1C). In addi-
tion to differences in CD56 and ITGA7 expression, variable
low-level expression of CD34 was noted in CD34
 /low
CD56
 ITGA7
low hMFA cells, compared to absent CD34
expression in CD34
 CD56
intITGA7
hi and CD34
 
CD56
hiITGA7
low cells (Figure S1H). PAX7 IF showed clear
enrichment of PAX7+ cells (78.3% ± 5%, mean ± SD) in
the CD34
 CD56
intITGA7
hi subset (Figure 2; red gate in
Figure 1C). In contrast, we detected no PAX7 expression
in CD34
 CD56
hiITGA7
low cells (Figures 2B and S2; blue
gate in Figure 1C) and variable PAX7 expression in
CD34
 /lowCD56
  ITGA7
low cells (33.0% ± 28%, mean ±
SD; Figures 2B and S2; green gate in Figure 1C).
Allcellpopulationsweresortedtwicetomaximizepurity.
The purity of double-sorted CD34
+, CD34
 /low, CD34
 
CD56
hiITGA7
low, and CD34
 CD56
intITGA7
hi cells was
consistently>99%uponreanalysis(FigureS3);however,re-
analysis of sorted CD34
 /lowCD56
 ITGA7
low cells showed
variable purities of 68.1% ± 26% (mean ± SD; Figure S3).
Variable contamination with CD34
 CD56
intITGA7
hi cells
could explain the variable levels of PAX7 expression de-
tected in the sorted CD34
 /lowCD56
 ITGA7
low cells. In
contrast, PAX7 enrichment in CD34
 CD56
intITGA7
hi cells
and absent PAX7 expression in CD34
 CD56
hiITGA7
low
was highly reproducible (n = 6 distinct donors for
CD34
 CD56
intITGA7
hi cell analysis and n = 3 donors for
CD34
 CD56
hiITGA7
low cell analysis; Figure 2B). Thus,
the canonical satellite cell marker PAX7 is selectively en-
riched in CD34
 CD56
intITGA7
hi fetal hMFA cells, suggest-
ingthathumanmyogenicprogenitorsmaybecontainedin
this population.
Figure 1. Cellular Heterogeneity in
Human Fetal Muscle
(A) hMFA cell differentiation under
myogenic, adipogenic, and osteogenic
conditions. Unfractionated hMFA cells
formed DESMIN
+, multinucleated myocytes
(left panel), oil red O
+ adipocytes (central
panel), and Alizarin red
+ calcium deposits
(right panel) under myogenic (left), adi-
pogenic (middle), or osteogenic (right)
conditions.
(B) Surface antigen expression within live
(Pi
 Ca
+ or 7AAD
 Ca
+) hMFA cells (mean ±
SD based on 3–20 biologically distinct
samples).
(C) Discrimination of phenotypically
distinct hMFA cells. Viable hMFA cells were
7AAD
  and Calcein blue
+ (left). Expression
of CD34 discriminated two populations
within CD45
 CD11b
 GlyA
 CD31
  cells
(middle). Among CD34
 /low cells (pink
gate), ITGA7 and CD56 identify three addi-
tional populations: CD34
 CD56
hiITGA7
low
(blue gate), CD34
 CD56
intITGA7
hi (red
gate), and CD34
 /lowCD56
-ITGA7
low (green
gate) cells (right).
See also Figure S1.
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FACS Isolation of Progenitors from Human MuscleCD34
 CD56
intITGA7
hi Fetal hMFA Cells Exhibit
Myogenic and Osteogenic Activity In Vitro but Lack
Adipogenic Differentiation Potential
We next evaluated the lineage potential of the fetal hMFA
cell subsets identiﬁed above using in vitro differentiation
assays. Under myogenic conditions (Figure 3, left panels),
CD34
 /low and CD34
 CD56
intITGA7
hi cells exhibited efﬁ-
cient myogenic differentiation, as evidenced by large
numbers of DESMIN
+ multinucleated myotubes. In
contrast, CD34
 /lowCD56
 ITGA7
low cells showed minimal
myogenic capacity. CD34
+ and CD34
 CD56
hiITGA7
low
cells, both of which lack PAX7 expression (Figure 2), ex-
hibitednomyogenicactivity.Underadipogenicconditions
(Figure 3, central panels), both CD34
+ and CD34
 /low cells
formed adipocytes (containing ORO-staining lipid drop-
lets). Within the CD34
 /low subset, only CD34
 /low
CD56
 ITGA7
low cells contained adipogenic activity, while
CD34
 CD56
intITGA7
hi and CD34
 CD56
hiITGA7
low cells
were uniformly nonadipogenic. These data suggest that
CD34
 /lowCD56
 ITGA7
low cells are responsible for
the adipogenic differentiation potential present among
CD34
 /low fetal hMFA cells. Finally, under osteogenic con-
ditions (Figure 3, right panels), both CD34
+ and CD34
 /low
cells formed AR-staining calcium deposits, consistent
with osteogenic differentiation. Myogenic CD34
 CD56
int
ITGA7
hi and CD34
 /lowCD56
 ITGA7
low cells also ex-
hibited osteogenic activity in these in vitro assays (Fig-
ure 3B, right panels).
Differences in the myogenic and adipogenic differentia-
tion capacity of fetal CD34
 CD56
intITGA7
hi cells and
CD34
+ cells remained evident under all the culture condi-
tions used. Speciﬁcally, myogenic CD34
 CD56
intITGA7
hi
cells still formed multinucleated myotubes under adipo-
genic(FigureS4A)andosteogenic(Figures3BandS4B) con-
ditions andnever formedadipocytes (FiguresS4AandS4B).
In contrast, CD34
+ cells formed adipocytes under adipo-
genic (Figures 3 and S4A) and osteogenic (Figure S4B) con-
ditions and never formed myotubes (Figures 3 and S4A).
Under myogenic conditions, CD34
+ cells adopted ﬁbro-
blastic morphology (data not shown).
In summary, these experiments reveal the following dif-
ferences in the in vitro myogenic, adipogenic, and osteo-
genic potentials of discrete, prospectively isolatable fetal
hMFA cell subsets: (1) PAX7-negative, CD34
 CD56
hi
ITGA7
low cells lack myogenic, adipogenic, and osteogenic
activity (Figures 2 and 3B); (2) PAX7-negative, CD34
+
cells contain adipogenic and osteogenic activity but
lack myogenic capacity (Figure 2 and Figure 3A); and
Figure 2. PAX7 Enrichment in CD34
 
CD56
intITGA7
hi Fetal hMFA Cells
(AandB)PAX7expressioninfetalhMFAcell
subsets was (A) determined by IF of freshly
sorted cells and (B) quantiﬁed as the
percentage of PAX7
+ cells among all DAPI
+
cells (mean ± SD; two to six biological
replicates). CD34
 CD56
intITGA7
hi cells are
highly enriched for PAX7 (mean ± SD,
78.3% ± 5%). Statistical signiﬁcance was
evaluated by unpaired, two-tailed t test
(**p < 0.001; ***p < 0.0001).
See also Figure S2.
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 CD56
intITGA7
hi cells (Figure 2)
contain myogenic and osteogenic capacity (Figure 4) but
lack adipogenic potential (Figure 3B).
Human Fetal CD34
 CD56
intITGA7
hi Cells Exhibit
Bipotent Myogenic/Osteogenic Differentiation
Activity In Vitro
The ability of PAX7-positive, CD34
 CD56
intITGA7
hi
human fetal cells to efﬁciently undergo myogenic differen-
tiation in vitro and form AR-positive calcium deposits
indicative of osteogenic differentiation is consistent with
previous reports of hMFA osteogenic differentiation
(Hashimoto et al., 2008; Lecourt et al., 2010; Oishi et al.,
2013). To determine whether this observation reﬂects
true bipotency, we clone-sorted CD34
 CD56
intITGA7
hi
cells into 96-well plates (one cell per well) and expanded
them for parallel analysis of myogenic and osteogenic
activity in vitro (Figure 4A). The efﬁciency of CD34
 
CD56
intITGA7
hi fetal hMFA cell clonal expansion was
variable and donor dependent, with an average seeding
efﬁciency of 7.1% ± 5.4% (mean ± SD; Figure 4B). We
succeeded in expanding 18 clones from four donors. After
14–22 days of expansion, these 18 clones were split and
replatedundermyogenicorosteogenicdifferentiationcon-
ditions. Under myogenic conditions, 100% (Figure 4B) of
clones differentiated into DESMIN-positive myotubes (Fig-
ure 4C; one representative clone shown). Under osteogenic
conditions, 82.5% ± 23.6% (mean ± SD; Figure 4B) of
clones formed AR-positive calcium deposits (Figure 4D;
one representative clone shown). We conclude that the
majorityoffetalCD34
 CD56
intITGA7
hihMFAcellspossess
bipotent myogenic and osteogenic differentiation poten-
tial in these in vitro assays.
To further investigate the potential of fetal CD34
 
CD56
intITGA7
hi cells, we determined their expression of
myogenic andosteogenic lineage genesat theend ofclonal
expansionandaftermyogenicorosteogenicdifferentiation
(Figure 4A). All (four out of four) CD34
 CD56
int
ITGA7
hi cell-derived clones analyzed by quantitative RT-
PCR (qRT-PCR) expressed both myogenic (MYOD and
DESMIN; Figures 4E and 4F) and osteogenic (RUNX2,
OSTERIX/SP7, and OSTEOCALCIN/BGLAP; Figures 4G–4I)
genes. Osteogenic lineage gene expression at the end of
in vitro clonal expansion and after myogenic and osteo-
genic differentiation corroborated the osteogenic activity
of human fetal CD34
 CD56
intITGA7
hi cells. Expression of
BGLAP increased signiﬁcantly in cells that underwent oste-
ogenic differentiation compared to proliferating clones;
however, BGLAP did not increase in cells that underwent
myogenic differentiation (Figure 4I). Increased expression
of RUNX2 and SP7 in CD34
 CD56
intITGA7
hi cells after
osteogenic differentiation in vitro was variable between
clones and did not reach statistical signiﬁcance (Figures
Figure 3. Differentiation of Fetal hMFA Cell Subsets under
Myogenic, Adipogenic, and Osteogenic Conditions
(A and B) hMFA cells were stained for DESMIN (red) and nuclei
marked byDAPI(blue) aftermyogenic culture(left panels),withoil
red O to mark lipid droplets after adipogenic culture (middle
panels), and with Alizarin red to mark calcium deposits after
osteogenic culture (right panels).
(A) CD34
+ cells lack myogenic activity but are adipogenic and
osteogenic in vitro, while fetal CD34
 /low cells contain myogenic,
adipogenic, and osteogenic activity in vitro.
(B) CD34
 CD56
hiITGA7
low cells lack myogenic, adipogenic, and
osteogenic capacity in vitro. CD34
 CD56
intITGA7
hi cells exhibit
efﬁcient myogenic activity, lack adipogenic potential, and contain
osteogenic activity in vitro. CD34
 /lowCD56
 ITGA7
low cells show
limited myogenic activity but are adipogenic and osteogenic
in vitro. Differentiation assays were performed in three biological
replicates for each population.
See also Figure S4.
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FACS Isolation of Progenitors from Human Muscle4G and 4H). Importantly, at least some CD34
 CD56
int
ITGA7
hi cells exposed to osteogenic differentiation condi-
tions maintained myogenic activity as evidenced by an
increase in DESMIN expression during osteogenic culture
(Figures 4F) and the presence of multinucleated myotubes
in these cultures (data not shown).
Human Fetal CD34
 CD56
intITGA7
hi Cells Engraft
Myoﬁbers when Transplanted into Mouse Skeletal
Muscle
To assess the contributions of FACS-isolated fetal hMFA
cells to muscle regeneration in vivo, we adapted previ-
ously published protocols to detect engraftment of unfrac-
tionated human myogenic cells in mouse muscle (Ehr-
hardt et al., 2007). Freshly isolated cells were injected
directly into the cardiotoxin preinjured tibialis anterior
muscles of immunodeﬁcient nonobese diabetic severe
combined immunodeﬁciency interleukin-2g
 /  mice
(NSG) mice, transplanted muscles were harvested
3–8 weeks after transplantation, and engraftment of hu-
man cells was detected by staining with antibodies against
the human membrane protein SPECTRIN (h-SPECTRIN).
H-SPECTRIN staining was strongly positive in fetal human
muscle sections (Figure 5A, left panel) and uniformly
Figure 4. Bipotent Osteogenic/Myogenic
Activity of CD34
 CD56
intITGA7
hi Fetal
hMFA Cells In Vitro
(A) CD34
 CD56
intITGA7
hi hMFA cells were
sorted at 1 cell per well into 96-well plates.
The clones were expanded and replated
under myogenic or osteogenic conditions.
(B) The colony-formation, myogenic, and
osteogenic differentiation capacity of
clones was evaluated. Myogenic differenti-
ation was observed in 100% of clones and
osteogenic differentiation in 83% (mean;
range 50%–100%) of clones (isolated from
four donors each).
(C) Myogenic differentiation (diff) capacity
was evaluated by IF for DESMIN (represen-
tative image of 1 of 18 clones).
(D) Osteogenic capacity was evaluated by
Alizarin red staining (representative image
of 1 of 18 clones).
(E–I) Myogenic (MYOD and DESMIN) and
osteogenic (RUNX2, SP7, BGLAP) differen-
tiation genes were evaluated by qRT-PCR
at the end of expansion (expans.),
myogenic, and osteogenic differentiation.
Fold-change differences relative to whole
human muscle were calculated for each
gene and condition and conﬁrm the bipo-
tency of CD34
 CD56
intITGA7
hi hMFA cells.
This assay was replicated in four biologi-
cally independent experiments. Statistical
signiﬁcance was evaluated by unpaired,
two-tailed t test (*p < 0.05; **p < 0.001;
ns, not signiﬁcant). Data are mean ± SD.
See also Figure S3.
Stem Cell Reports j Vol. 2 j 92–106 j January 14, 2014 j ª2014 The Authors 97
Stem Cell Reports
FACS Isolation of Progenitors from Human MuscleFigure 5. In Vivo Engraftment of Fetal hMFA Cell Subsets in Mouse Muscle
Engrafted hMFAcells were detectedin transplanted NSGmouse muscle bycostainingfor humanspecies-speciﬁc h-SPECTRIN (h-SPEC, red),
muscle-speciﬁc DYSTROPHIN (DYS, green), and DAPI (blue).
(A) Species-speciﬁc staining for h-SPEC is strongly positive in human muscle (left) and absent in mouse muscle (middle). Unfractionated
hMFA cells engrafted to form h-SPEC-positive cells in four out of four transplanted mice (right).
(legend continued on next page)
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FACS Isolation of Progenitors from Human Muscleabsent in mouse muscle sections (Figure 5A, middle
panel). Engraftment of unfractionated fetal hMFA cells,
as evidenced by the presence of h-SPECTRIN
+ cells on se-
rial sections of transplanted muscles, was detected in four
out of four transplanted mice (injected with 900,000 cells
per mouse, isolated from two donors in two independent
experiments; Figure 5A, right panel). To assess the in vivo
myogenic activity of sorted fetal hMFA cell subsets, cells
were isolated from 11 individual donors and transplanted
into the cardiotoxin preinjured tibialis anterior muscles of
NSG recipients. Engraftment by human cells, marked by
staining with h-SPECTRIN, was detected in 6 of 28 mus-
cles transplanted with CD34
 CD56
intITGA7
hi fetal hMFA
cells (37,000–100,000 cells injected), 8 of 25 muscles
transplanted with CD34
+ fetal cells (37,000–100,000
cells injected), three of ten muscles transplanted with
CD34
 /lowCD56
 ITGA7
low fetal cells (20,000–100,000
cells injected), and three of ten muscles transplanted
with CD34
 CD56
hiITGA7
low fetal cells (7,000–100,000
cells injected) (Figure 5B, top panels, and Figure 5C).
Similar numbers of h-SPECTRIN-positive cells were
detected in muscles engrafted with human CD34
 
CD56
intITGA7
hi cells (12 ± 3; mean ± SEM). CD34
+ cells
(8 ± 3; mean ± SEM), CD34
 /lowCD56
 ITGA7
low cells
(11 ± 5; mean ± SEM), or CD34
 CD56
hiITGA7
low
cells (5 ± 2; mean ± SEM) (Figure 5D).
We next evaluated myogenic engraftment of fetal hMFA
cell subsets in transplanted mouse muscles by costaining
for h-SPECTRIN (Figure 5B, top panels) and DYSTROPHIN
(Figure 5B, middle panels), a membrane protein expressed
in both mouse and human muscle ﬁbers. Costaining of
h-SPECTRIN and DYSTROPHIN (Figure 5B, bottom panels,
and Figure S5) in four of six muscles engrafted with fetal
human CD34
 CD56
intITGA7
hi cells indicated that the
transplanted cells underwent myogenic differentiation
and contributed to the formation of mature ﬁbers. A total
of 35%–100% of h-SPECTRIN
+ cells in these muscles
coexpressed DYSTROPHIN. In contrast, none (0%) of the
h-SPECTRIN+ cells detected in muscles engrafted with
fetal CD34
+ cells, CD34
 /lowCD56
 ITGA7
low cells, or
CD34
 CD56
hiITGA7
low cells were DYSTROPHIN
+ (Fig-
ure 5E). Thus, only fetal CD34
 CD56
intITGA7
hi hMFA
cells are capable of myogenic engraftment in mouse
muscle.
The Transcriptional Signatures of Fetal hMFA Cell
Subsets Are Consistent with Lineage-Speciﬁc
Differences in Their Differentiation Capacities
Togaindeeperinsightsintothemolecularunderpinningsof
CD34
 CD56
intITGA7
hi cells andCD34
+ adipogenic precur-
sorswithinthefetalhMFAcellpool,thetranscriptionalpro-
ﬁle of these functionally distinct populations, as compared
to unfractionated fetal hMFA cells, was evaluated. Principal
component analysis (PCA; Figure 6A) and hierarchical
cluster analysis (Figure 6B) showed clustering of CD34
 
CD56
intITGA7
hi cells, CD34
+ cells, and hMFA cells into
three transcriptionally distinct populations. Comparison
of CD34
 CD56
intITGA7
hi cells (12.2% ± 4.3% of live fetal
hMFA cells; Table S1) to unfractionated hMFA cells identi-
ﬁed 5,686 differentially regulated probesets, and compari-
son of CD34
+ cells (62.7% ± 7.8% of live fetal hMFA cells;
Table S1) to unfractionated hMFA cells yielded 1,029
differentially regulated probesets (>1.5-fold difference
up or down and p < 0.05). Notably, there was no over-
lap between these groups of differentially regulated
genes. Ingenuity pathway analysis revealed that within
the group of genes most highly upregulated in fetal
CD34
 CD56
intITGA7
hi cells as compared to CD34
+ cells
(>5-fold difference, p < 0.01, total 346 genes; Table S2), the
25 top-scoring functions involved muscle development,
differentiation, or function (Table S3). Interestingly, within
the group of genes most highly upregulated in CD34
+ cells
versus CD34
 CD56
intITGA7
hi cells (>5-fold difference,
p < 0.01, total 854 genes; Table S4), the seven top-scoring
functions involved solid tumor malignancy (Table S5).
We also speciﬁcally analyzed expression by freshly iso-
lated fetal CD34
 CD56
intITGA7
hi cells and CD34
+ cells of
certain myogenic lineage (PAX7, MYF5, M-CADHERIN/
CDH15, MYOD, MYOG), adipogenic lineage (PPARG,
FABP4) and osteogenic lineage (COL1A, ALPL, BGLAP,
RUNX2) genes in the microarray data set (Figure 6C).
Expression of satellite cell markers (including the HGF
receptorMET;FigureS6C)andmyogenicgeneswasupregu-
lated in fetal CD34
 CD56
intITGA7
hi hMFA cells, whereas
adipogenic genes were upregulated in fetal CD34
+ cells
(Figure 6C). Expression of osteolineage genes was detected
in both CD34
 CD56
intITGA7
hi cells and CD34
+ cells
(Figure 6C), consistent with the osteogenic activity of
both populations. Finally, we conﬁrmed differential
(B)EngraftedfetalCD34
 CD56
intITGA7
hihMFAcellsformedmyoﬁbersasdemonstratedbycostainingforh-SPECandDYS.EngraftedCD34
+,
CD34
 CD56
hiITGA7
low, and CD34
 /lowCD56
 ITGA7
low cells formed h-SPEC+, DYS  cells.
(C) Engraftment efﬁciency was calculated for each subset as the number of muscles engrafted (i.e., h-SPEC+ cells present) of all muscles
transplanted.
(D) Engraftment was quantiﬁed as the maximum number of h-SPEC+ cells per engrafted muscle section. Data are mean ± SEM.
(E) Myogenic engraftment was quantiﬁed as the percentage of h-SPEC+ cells that were also DYS+. Statistical signiﬁcance was evaluated by
unpaired, two-tailed t test (*p < 0.05; **p < 0.001; ns, not signiﬁcant). Data are mean ± SEM.
See also Figure S5.
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FACS Isolation of Progenitors from Human Muscleexpression of adipogenic, osteogenic, and myogenic line-
age-speciﬁc genes (PPARG, FABP4, BGLAP, RUNX2, PAX7,
and MYF5) in fetal CD34
 CD56
intITGA7
hi and CD34
+
hMFA cells by qRT-PCR (Figure 6D). Levels of PPARG
(fold-change  47 ± 20), FABP4 (fold-change  10 ± 2) and
BGLAP (fold-change  4 ± 3) were reduced in
CD34
 CD56
intITGA7
hi cells compared to CD34
+ cells. In
contrast, PAX7 (fold-change +513 ± 70) and MYF5 (fold-
change +674 ± 31) levels were increased in CD34
 CD56
int
ITGA7
hi cells, consistent with their myogenic function.
Thus, sorted CD34
 CD56
intITGA7
hi cells and CD34
+ cells
fromfetalhumanmusclepossesstranscriptionalsignatures
highly consistent with their distinct differentiation
potentials.
Figure 6. Distinct Transcriptional Signatures of Fetal CD34
 CD56
intITGA7
hi and CD34
+ hMFA Cells
(A and B) PCA (A) and hierarchical clustering (B) demonstrate distinct gene expression signatures of CD34
+ cells (blue, CD34
+),
CD34
 CD56
intITGA7
hi cells (red, CD34
 CD56
intITGA7
hi), and unfractionated hMFA cells (green). Microarray analysis was performed using
three to four (see B) biologically independent, freshly sorted CD34
 CD56
intITGA7
hi, CD34
+, and unfractionated hMFA cell samples.
(C) Microarray analyses demonstrated increased expression of muscle-lineage genes (PAX7, MYF5, CDH15, MYOD, MYOG)i n
CD34
 CD56
intITGA7
hi cells andadipocyte-lineage genes (PPARG andFABP4) inCD34
+ cells. Osteolineage genes (COL1A1, ALPL, BGLAP,and
RUNX2) were present in fetal CD34
 CD56
intITGA7
hi cells and CD34
+ cells (blue, downregulated genes; red, upregulated genes).
(D) Expression of PAX7, MYF5, PPARG, FABP4, BGLAP, and RUNX2 (relative to GAPDH) was evaluated by qRT-PCR in fetal CD34
 
CD56
intITGA7
hicellscomparedtoCD34
+cellsobtainedfromtwobiologicallyindependentfetalCD34
 CD56
intITGA7
hiandthreebiologically
independent CD34
+ cells samples. PAX7 and MYF5 levels are 512- to 670-fold greater, and PPARG, FABP4, BGLAP, and RUNX2 levels are 8- to
60-fold lower, in CD34
 CD56
intITGA7
hi hMFA cells as compared to CD34
+ cells. Data are mean ± SD.
See also Figure S6.
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FACS Isolation of Progenitors from Human MuscleFinally, our microarray analyses identiﬁed a number of
additional surface markers as differentially regulated in
fetal CD34
 CD56
intITGA7
hi and CD34
+ hMFA cells,
including increased levels of MCAM (Figure S6B), CD144
(Figure S6B), and PROMININ1 (CD133; Figure S6B) and
decreased levels of PDGFRA (CD140a; previously reported
to mark adipocyte precursors; Berry and Rodeheffer,
2013; Figure S6B) in CD34
 CD56
intITGA7
hi as compared
to CD34
+ cells (Table S6).
Adult Skeletal Muscle Shows Reduced Content of
PAX7-Expressing CD34
 CD56
intITGA7
hi hMFA Cells
with Myogenic and Osteogenic Activity
To determine whether the surface marker combination
we identiﬁed as marking PAX7-expressing osteogenic/
myogenic progenitors in human fetal muscle would simi-
larly mark progenitors in adult tissue, we evaluated differ-
ential expression of surface markers (Figure 7A), PAX7
enrichment (Figure 7B), myogenic differentiation (Fig-
ure 7C), and osteogenic differentiation (Figure S7)i n
hMFA cells obtained from discarded human adult muscle.
FACS analysis indicated clear separation of CD34
+ and
CD34
 /low subsets within the pool of viable CD45
 
CD11b
 GlyA
 CD31
  adult hMFA cells (Figure 7A). As in
fetal muscle, all myogenic activity was contained within
the CD34
 /low subset of adult hMFA cells, whereas CD34
+
cells were uniformly nonmyogenic (Figure 7C). However,
within the CD34
 /low adult hMFA cell pool, expression of
CD56 and ITGA7 discriminated only two cell populations:
CD34
 /lowCD56
 ITGA7
low and CD34
 CD56
intITGA7
hi
cells. The CD34
 CD56
hiITGA7
low subset detected in fetal
muscle was not present in adult muscle (Figure 7A). We
conﬁrmed selective enrichment of PAX7-expressing cells
(89% ± 7%, mean ± SD; Figure 7B) and in vitro myogenic
activity (Figure 7C, second panel from right) in adult
CD34
 CD56
intITGA7
hi hMFA cells. Finally, analogous to
fetal cells, adult CD34
 CD56
intITGA7
hi cells exhibited
osteogenic activity (Figure S7A) and lacked adipogenic
potential (Figure S7B) in vitro, in addition to their
myogenic function. Thus, CD34
 CD56
intITGA7
hi hMFA
cells isolated from adult muscle, similar to cells of the
same marker phenotype obtained from fetal muscle, are
PAX7-expressing cells with osteogenic/myogenic activity.
However, total hMFA cell numbers were signiﬁcantly lower
in adult muscle (mean of 0.4 3 10
6 [adult] versus 2.5 3 10
6
[fetal] hMFA cells per gram muscle; p = 0.0001; Figure 7D),
and the percentage of CD34
 CD56
intITGA7
hi cells among
hMFA cells was also lower (mean of 12.2% ± 1.7% [fetal]
versus 1.5% ± 1.7% [adult]; p < 0.0001; Figure 7F). This
translated into an  2-log reduction in the total number
of CD34
 CD56
intITGA7
hi hMFA cells in adult as compared
to fetal muscle (mean 3.3 3 10
5 [fetal] versus 3.6 3 10
3
[adult] cells per gram of muscle; p = 0.0002; Figure 7E).
Decreasing muscle progenitor frequency with age in
human muscle is consistent with previously published
ﬁndings in the mouse (Conboy et al., 2003).
DISCUSSION
Recent advances enabling the prospective isolation of
mouse satellite cells have facilitated mechanistic analyses
of their myogenic function. For example, the ability to
clonally sort satellite cells with high purity made possible
thedemonstrationthatthesecellscanundergoasymmetric
division (Kuang et al., 2007; Rocheteau et al., 2012) and re-
populate the satellite cell niche in vivo (Cerletti et al.,
2008). While ﬁndings in mouse models are often extrapo-
lated to human biology, whether mouse and human
myogenic cells exhibit fully equivalent properties may still
be questioned, particularly given signiﬁcant phenotypic
discrepancies in several mouse models of human muscle
disease (Bulﬁeld et al., 1984). All of these issues can be
addressed through the establishment of robust methods
for direct puriﬁcation of human muscle progenitors.
Previous work by Pisani et al. demonstrated the utility of
the sialomucin CD34 to enrich for myogenic cells within
the CD34
  subset of magnetically separated cells in adult
muscle (Pisani et al., 2010b), consistent with immunohis-
tochemical studies reporting the absence of CD34 in adult
human muscle cells located in the satellite cell position
(Lecourt et al., 2010). Pisani et al. also noted mixed
myogenic and adipogenic activity within CD34
+ adult
muscle cells, which showed differential expression of
CD56 (Pisani et al., 2010a). Findings from our study
conﬁrm that CD34 distinguishes myogenic and nonmyo-
genic cells within the nonhematopoietic, nonendothelial
(CD45
 CD11b
 GlyA
 CD31
 ) hMFA cell pool in both
fetal and adult tissue: CD34
+ cells are PAX7-negative,
adipogenic cells that do not possess any myogenic
activity, whereas within the CD45
 CD11b
 GlyA
 CD31
 
CD34
 /low subset, selection of CD56
intITGA7
hi cells yields
a highly enriched population of PAX7-expressing, robustly
myogenic progenitors. Yet, it is important to note that
these FACS-based strategies pertain to cells isolated from
fresh muscle only. Sorted cells may undergo marked
changes in their surface marker proﬁles during ex vivo cul-
ture, and it is unclear if our protocols are applicable to cells
that have undergone expansion/differentiation in culture.
Fluorescence-activated cell-sorted fetal human CD34
 
CD56
intITGA7
hi cells engraft in mouse muscle to form
new myoﬁbers, albeit at low efﬁciency (Figures 5B–5F).
Low-level engraftment of human cells into mouse tissue
is not unexpected, as similar outcomes have been observed
for other human, tissue-speciﬁc stem and progenitor cells
upon transfer into immune-compromised mice (Doulatov
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FACS Isolation of Progenitors from Human MuscleFigure 7. Adult CD34
 CD56
intITGA7
hi hMFA Cells Are PAX7-Expressing Myogenic Progenitors
(A) FACS gating strategy for isolation of CD45
 CD11b
 GlyA
 CD31
 CD34
 CD56
intITGA7
hi cells within live (7AAD
  Calcein
+) hMFA cells.
(B) PAX7 expression (red) is enriched in CD34
 CD56
intITGA7
hi hMFA cells (89% ± 7% [mean ± SD] Pax7
+), as assessed by IF. Nuclei were
marked by DAPI (blue).
(legend continued on next page)
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FACS Isolation of Progenitors from Human Muscleet al., 2012; Racki et al., 2010). Unfortunately, given the
relatively sparse presence of human myoﬁbers in this sys-
tem, we were unable to establish conditions to reliably
detect costaining for PAX7 and human species-speciﬁc
nuclear antigens on engrafted mouse muscle sections. We
therefore were unable to determine if ﬂuorescence-acti-
vated cell sorted fetal human CD34
 CD56
intITGA7
hi cells
can repopulate the PAX7-expressing satellite cell pool
invivo.We alsowereunabletotesttheinvivoengraftment
potential of ﬂuorescence-activated cell-sorted progenitors
from adult human muscle, given the low yield of cells
that could be obtained from adults (Figure 7E).
Interestingly, enrichment of PAX7 expression and
myogenic activity within the CD34
  compartment in
human muscle stands in contrast to immunophenotyping
studies in mouse muscle, which localize myogenic activity
to the CD34
+ subset of mouse MFA cells (Beauchamp et al.,
2000; Conboy et al., 2010; Montarras et al., 2005; Sacco
et al., 2008; Sherwood et al., 2004). Species-speciﬁc differ-
ences in CD34 expression have also been noted in other
somatic stem cell populations, including hematopoietic
stem cells (HSCs), which are CD34
+ in adult human bone
marrow and CD34
  in adult mouse bone marrow (Okuno
et al., 2002; Osawa et al., 1996). Such differences appear to
arise from the presence of species-speciﬁc upstream regula-
toryelements,whichdifferentiallyregulateCD34genetran-
scription in mouse and human cells (Okuno et al., 2002).
Cell surfacemarkers that have proveduseful forthe isola-
tion of mouse PAX7
+ satellite cells include ITGA7 (Pasut
et al., 2012; Sacco et al., 2008), CXCR4 and b1 INTEGRIN
(Sherwood et al., 2004), and VCAM1 (Chakkalakal et al.,
2012). Our studies indicate that PAX7-expressing cells in
fetal and adult human muscle coexpress ITGA7 and
CD56, although neither of these markers alone is sufﬁcient
todistinguishthesecells.ThisisconsistentwithITGA7and
CD56 expression by human myogenic progenitors derived
from PAX7-expressing induced pluripotent stem cells (Dar-
abi et al., 2012). Clear expression of CXCR4 was observed
in adult and fetal PAX7-expressing cells (Figure S6A), and
b1-INTEGRIN was detected on 90% of hMFA cells (Fig-
ure 1B). Additional surface marker analyses, focusing
particularly on those previously linked to mouse and/or
human myogenic precursors (Cerletti et al., 2012; Darabi
et al., 2012; Lecourt et al., 2010; Zheng et al., 2007), re-
vealed increased expression of MCAM (CD146) and CD44
in human fetal CD34
 CD56
intITGA7
hi cells as compared
toCD34
+cells(FigureS6B).Finally,ourmicroarrayanalyses
suggest that PROMININ1 (CD133) and PDGFRA (CD140a;
previously reported to mark adipocyte precursors; Berry
and Rodeheffer, 2013) could also be useful in distinguish-
ing human myogenic progenitors, as they are differentially
expressed in fetal CD34
 CD56
intITGA7
hi cells and CD34
+
cells (Figure S6C; Table S6).
MFA cells obtained from mouse and human muscle were
previously shown to exhibit osteogenic activity (Glass
et al., 2011; Hashimoto et al., 2008; Lecourt et al., 2010;
Oishi et al., 2013). In our studies, both fetal and adult
PAX7-expressing CD34
 CD56
intITGA7
hi cells formed AR-
positive calcium deposits and expressed osteogenic lineage
genes under osteogenic conditions, consistent with prior
reports of osteogenic differentiation potential within the
pool of muscle cells containing PAX7
+ progenitors (Hashi-
moto et al., 2008; Ozeki et al.,2006). Clonalassays revealed
that the osteogenic activity of human fetal CD34
 
CD56
intITGA7
hi hMFA cells is unlikely to be attributable
to contamination by other cells, as the majority of clone-
sorted cells exhibited bipotent myogenic and osteogenic
activity. Future studies are needed to investigate adult
muscle progenitor bipotency and delineate the events
that trigger possible osteogenic differentiation of human
CD34
 CD56
intITGA7
hi cells, their possible contributions
to normal bone regeneration, and their relationship to
other mesenchymal precursor cells.
In contrast to fetal CD34
 CD56
intITGA7
hi cells, which
exhibit robust myogenic activity and lack adipogenic
potential, human fetal CD34
+ cells are adipogenic and
lack myogenic capacity. While our studies evaluated the
ability of these cells to form white adipocytes, a previous
report indicates that CD34
+ cells in fetal and adult human
muscle contain brown adipogenic activity as well (Crisan
et al., 2008). Gene expression proﬁling conﬁrms profound
differences in the transcriptional signatures of fetal human
CD34
 CD56
intITGA7
hi and CD34
+ hMFA cells, with in-
creased expression of muscle lineage genes in CD34
 
CD56
intITGA7
hi cells and increased expression of adipo-
genic genes in CD34
+ cells. Given their differentiation
proﬁle, we speculate that CD34
+ hMFA cells may represent
the human counterparts of the ﬁbroadipogenic precursor
(FAP) population inmouse muscle (Joe et al., 2010; Uezumi
et al., 2010), an important subset of nonmyogenic cells
that appears to enhance muscle regenerative capacity (Joe
et al., 2010).
(C) Myogenic differentiation assays showed that in vitro myogenic activity is highly enriched in adult CD34
 CD56
intITGA7
hi cells and
absent from CD34
+ and CD34
 /lowCD56
 ITGA7
low cells.
(D–F)Numbers of hMFA cells (D) or CD34
 CD56
intITGA7
hi cells (E) per gram of tissue, and frequency of CD34
 CD56
intITGA7
hi cells (F), were
compared for adult and fetal muscle. Statistical signiﬁcance was evaluated by unpaired, two-tailed t test.
Data are mean ± SD.
See also Figure S7.
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FACS Isolation of Progenitors from Human MuscleIn summary, we report functionally distinct cell popula-
tions within the hMFA cell pool in fetal and adult muscle
and provide a speciﬁc method for the prospective isolation
of puriﬁed PAX7
+ cells from human muscle. We anticipate
that this technology will facilitate novel insights into hu-
man muscle homeostasis, aging, and disease. Phenotypi-
cally distinct cells with myogenic progenitor function also
represent promising targets for muscle regenerative cell
therapy and could conceivably be used to treat a variety of
diseases,includingmusculardystrophyandmuscleinjuries.
EXPERIMENTAL PROCEDURES
Human Skeletal Muscle Specimens
Human fetal muscle was obtained from 20- to 23-week-gestation
fetuses and adult muscle from deceased volunteers or discarded
during surgery (Table S1). Use of human tissues was approved by
relevant institutional review boards.
Isolation of hMFA Cells
hMFA cells were isolated by two-step enzymatic digestion and
mechanical dissociation as per previously published protocols
(Sherwood et al., 2004).
Antibody Staining and FACS
Primary and secondary antibodies used for FACS are listed in Table
S7. All cell populations were sorted twice to maximize purity.
PAX7 IF and Quantiﬁcation
hMFAcellsubsetsweresorteddirectlyinto40mlofPBSspottedona
glass slide (5 3 10
3 cells per slide) according to protocols adapted
from (Ema et al., 2006). Sorted cells were stained with PAX7
(DSHB, 10 mg/ml).
Myogenic Differentiation Assay
hMFA cell subsets were sorted in 96-well plates, expanded in
myogenic growth medium for 7 days, transitioned into differenti-
ation medium for 4–5 days, and ﬁxed and stained with DESMIN
antibody (clone D33, M0760, titer 1:50; Dako).
Adipogenic Differentiation Assay
hMFAcellsubsetsweresortedin96-wellplates,expandedinadipo-
genic growth medium until conﬂuent (13–14 days), transitioned
into adipogenic induction medium for 3 days, placed in differenti-
ation medium for 4 days, and ﬁxed and stained with ORO (Sigma).
Osteogenic Differentiation Assay
hMFA cell subsets were sorted in 96-well plates, expanded in prea-
dipocyte medium (PM-1, ZenBio) + 25 ng/ml basic ﬁbroblast
growth factor (Sigma) until conﬂuent (13–14 days), transitioned
into osteoblast differentiation medium (OB-1, ZenBio) for
14 days, and ﬁxed and stained with 2% AR (Sigma).
Clonal Cell Culture
Fetal hMFA cell subpopulations were sorted at 1 cell per well in
96-well plates in myogenic growth medium. After 9–10 days, the
number of wells with visible cell growth was determined. Cells
were kept in myogenic growth conditions until conﬂuent and
passaged into myogenic or osteogenic differentiation assays.
Transplantation Studies
NSG mice (JacksonLaboratory) were bred and maintained at Joslin
DiabetesCenterunderInstitutionalAnimalCareandUseCommit-
tee-approved protocols. The tibialis anterior (TA) muscle of 6- to
8-week-old NSG mice was conditioned 24 hr prior to transplanta-
tion by injection of 25 ml (0.03 mg/ml) of Naja mossambica
mossambica cardiotoxin (CTX, Sigma). Recipient muscles were
harvested 3–8 weeks after transplantation. Engraftment was evalu-
ated by IF staining of 7 mm sections for h-SPECTRIN (human
species-speciﬁc) and DYSTROPHIN. Tissue was blocked using
Papain-digested RAM antibodies supplemented with goat Fc anti-
bodies at 5 mg/ml and 5% fetal bovine serum according to previ-
ously published protocols (Ehrhardt et al., 2007).
Microarray Analysis
Total RNA was extracted using TRIzol labeled and hybridized to
Affymetrix microarrays (Human Genome U133 Plus 2.0). Raw
data were normalized and differentially regulated probesets were
identiﬁed using GenePattern. Hierarchical clustering was per-
formed in GenePattern (Broad Institute), PCA using 3D-PCA, and
pathway analysis using Ingenuity.
PCR
Total RNA was extracted using TRIzol, reverse transcribed using
Superscript III First-Strand Synthesis System (Invitrogen). qRT-
PCR was performed using an AV7900 PCR system (Applied Bio-
systems) and TaqMan Gene Expression Assays (Invitrogen).
Statistics
Statistical analysis was performed using two-tailed Student’s t test
for unpaired data when appropriate. p values are indicated with
asterisks (*p < 0.05, **p < 0.001, and ***p < 0.0001) and NS (not
signiﬁcant).
For additional details regarding experimental procedures, please
see the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The microarray data reported in this paper were deposited in
the NCBI Gene Expression Omnibus under accession number
GSE44227.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven ﬁgures, and seven tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.12.006.
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